In a retrospective service evaluation of patients with MPNs, researchers found that low-dose methotrexate eased symptom burden of comorbidities not related to the patient’s MPN.
In this prospective study, researchers investigated the incidence of pulmonary hypertension among patients with MPNs. Their results led them to recommend systematic screening in this patient population.
An overview of the findings of an expert panel that examined the unmet clinical needs for patients with Ph-negative MPNs to assess for risks of thrombosis.
Although extreme thrombocytosis occurs rarely, researchers were able to identify its underlying cause and potential prognosis for patients who develop the condition.
An expanded treatment protocol study sought to validate the safety and efficacy of ruxolitinib, a JAK kinase inhibitor approved by the FDA for the treatment of polycythemia vera in patients who are intolerant of, or resistant to, hydroxyurea.